comparemela.com
  1. Home
  2. Live Updates
  3. Neil Vasan - Breaking News

Latest Breaking News On - Neil vasan - Page 1 : comparemela.com

FDA advisers back new endpoint for myeloma approvals, paving way for faster introduction of new drugs

FDA advisers back new endpoint for myeloma approvals, paving way for faster introduction of new drugs
fiercepharma.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from fiercepharma.com Daily Mail and Mail on Sunday newspapers.

Bristol myers squibb revlimidRichard pazdurMichael riottoCarl ola landgrenNeil vasanSanofi sarclisaAmgen kyprolisRachel ershlerInternational myeloma foundationUniversity of california san franciscoSylvester comprehensive cancer centerColumbia universityInternational myelomaCalifornia san franciscoBristol myers squibbFierce pharma

Revamping Science for Improved Breast Cancer Drugs

Revamping Science for Improved Breast Cancer Drugs
miragenews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from miragenews.com Daily Mail and Mail on Sunday newspapers.

Neil vasanJeff clarkDivision of hematologyColumbia university irving medical center neil vasanHerbert irving comprehensive cancer centerColumbia university irving medical centerHerbert irving comprehensive cancer

FDA panel finds KRAS drug data unreliable, in blow to Amgen

BioPharma

Neil vasanMark conawayJames pantelasHarpreet singhUniversity of virginia school medicineColumbia university medical centerDrug administrationDive briefVirginia schoolMirati therapeuticsClinical trials

Sotorasib s Confirmatory Data in NSCLC Unreliable, Says FDA Panel

But agency doesn't plan to immediately push for KRAS inhibitor's withdrawal

New yorkUnited statesColumbia universityRichard pazdurNeil vasanLos angelesMike bassettHarpreet singhJorgej nievaDaniel sprattMark conawayColumbia university medical centerOncologic drugs advisory committeeOncology centerUniversity of virginiaCase western reserve university in cleveland

FDA Panel Rejects Broad Olaparib Indication in Metastatic CRPC

ODAC votes that olaparib-abiraterone combination should be restricted to <em>BRCA</em>-positive subset

United statesNorth carolinaColumbia universityNew yorkMike bassettChana weinstockDaniel georgeLos angelesRichard pazdurNeil vasanJorge nievaAstrazeneca laurence tomsDuke cancer institute in durhamColumbia university medical centerOncology centerOffice of oncologic diseases

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.